An interventional study of Spot stent system and Self-expanding peripheral stent system in Peripheral Vascular Disease (PVD) and Peripheral Arterial Disease (PAD), sponsored by Acotec Scientific Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-29.
Sponsored by Acotec Scientific Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.
Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 21st largest by planned enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2022, is one of 34 with no phase, reaches primary completion later than 6 of the 33 other live ones, and was the 39th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 18–100 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Argentina and 15 more countries
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18+
Sirius Therapeutics Co., Ltd. · Sites in China
Ages 18–75
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 1
First in 2008; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 196 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 167 across the 53 interventional studies, 254 across the 27 observational. Of the 25 that completed or were terminated, 5 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 80 have an industry lead sponsor. The 10 most frequent:
Acotec Scientific Co., Ltd is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Acotec Scientific Co., Ltd has 8 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Peripheral Arterial Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06539689FrontAce Scientific Co., LtdA Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries | 2026-12-04 |
| NCT07397390The First Affiliated Hospital of Dalian Medical Universityan Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vessel Preparation Facilitated by IVUS on the Lower Limb Ischemia Patients With Calcified Lesions | 2026-12-30 |
| NCT07602634Zhijun BaoRadiomics Features Predicting Outcomes of PAD | 2026-12-31 |
| NCT03791970Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityStents Post-dilation With DCB or POBA in Femoropopliteal Arteries | 2026-12-31 |
| NCT07860138Fudan UniversityHemodynamic Characteristics of Peripheral Arterial Disease Using Computational Fluid Dynamics | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 80 studies in Peripheral Arterial Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective randomized trial designed to compare the efficacy and safety of spot stent system versus self-expanding peripheral stent system in the endovascular treatment of femoropopliteal arterial stenotic disease.
The objective of this clinical investigation is to assess the efficacy and safety of spot stent system ,which is indicated for use in patients with atherosclerotic disease of the superficial femoral artery (SFA) or proximal popliteal arteries and for the treatment of insufficient results after percutaneous transluminal angioplasty.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
This study's planned enrollment of 196 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Browse Peripheral Arterial Disease studies →Acotec Scientific Co., Ltd is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Compared within Peripheral Arterial Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Vascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A system that loaded multi low radial force stents on one catheter.
Device: Spot stent system
A conventional stent system that commonly used.
Device: Self-expanding peripheral stent system
Spot stent system designed and produced by Acotec
Self-expanding peripheral stent system designed and produced by Ev3, Inc
The primary patency rate of target lesion at 12 months post-procedure
Defined as freedom from clinically driven target lesion revascularization (CD-TLR) and binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4)
Time frame: 12 months post-procedure
Rate of device success
Defined as successful delivery, release and retrieval of the device.
Time frame: immediate post-procedure
Rate of procedural success
Defined as no provisional stent implanted or major adverse event occured prior to discharge.
Time frame: 7 days post-procedure
Rate of clinically driven target lesion revascularization within 12 months post-procedure
Defined as any reintervention at the target lesion due to the following symptoms: drop of ABI \>20% or ABI \>0.15 compared to the post-procedure ABI
Time frame: 12 months post-procedure
The change of Rutherford class from baseline
Defined as change in target limb Rutherford class from baseline to 12 months
Time frame: 12 months post-procedure
The change of ankle-brachial index (ABI) from baseline
Defined as change of target limb ABI from baseline to 12 months
Time frame: 12 months post-procedure
Rate of composite safety endpoint
Defined a composite rate of all cause death, major target limb amputation (above-the-ankle amputation), clinically driven target lesion revascularization (CD-TLR) through 30 days post- procedure
Time frame: 30 days post-procedure
Started Aug 2022 (actual). Primary completion is estimated for Nov 2024, 27 months after the start.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 27 months is close to that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acotec Scientific Co., Ltd